174 related articles for article (PubMed ID: 37548555)
1. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
[TBL] [Abstract][Full Text] [Related]
2. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
[TBL] [Abstract][Full Text] [Related]
3. Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Montorsi F; Moschini M; Gandaglia G; Briganti A
J Urol; 2024 Mar; 211(3):482-483. PubMed ID: 38329052
[No Abstract] [Full Text] [Related]
4. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Lee HW; Lee HH; Park EY; Park WS; Kim SH; Joung JY; Chung J; Seo HK
J Urol; 2023 Jan; 209(1):131-139. PubMed ID: 36250938
[TBL] [Abstract][Full Text] [Related]
5. Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
Stover AM; Basak R; Mueller D; Lipman R; Teal R; Hilton A; Giannone K; Waheed M; Smith AB
J Urol; 2022 Sep; 208(3):580-588. PubMed ID: 35640276
[TBL] [Abstract][Full Text] [Related]
6. Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Moschini M; Salonia A; Briganti A; Montorsi F
Eur Urol; 2023 Oct; 84(4):439-440. PubMed ID: 36967362
[No Abstract] [Full Text] [Related]
7. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. Letter.
Peng CK; Sung WW; Chen SL
J Urol; 2023 May; 209(5):845-846. PubMed ID: 36893470
[No Abstract] [Full Text] [Related]
8. Randomized study of intravesical pirarubicin chemotherapy with low and intermediate-risk nonmuscle-invasive bladder cancer in Japan: Comparison of a single immediate postoperative intravesical instillation with short-term adjuvant intravesical instillations after transurethral resection.
Naya Y; Mikami K; Takaha N; Inoue Y; Fujihara A; Kanazawa M; Nakanishi H; Miyashita H; Ukimura O
Medicine (Baltimore); 2018 Oct; 97(42):e12740. PubMed ID: 30334959
[TBL] [Abstract][Full Text] [Related]
9. Patient and Provider Perception of Transurethral Resection of Bladder Tumor vs Chemoablation for Nonmuscle-invasive Bladder Cancer Treatment.
Parisse T; Reines K; Basak R; Mueller D; Teal R; Vu MB; Carda-Auten J; Stein K; Giannone K; Lipman R; Smith AB
J Urol; 2023 Jan; 209(1):150-160. PubMed ID: 36067365
[TBL] [Abstract][Full Text] [Related]
10. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
11. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
[TBL] [Abstract][Full Text] [Related]
12. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
13. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
Richards KA; Smith ND; Steinberg GD
J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
[TBL] [Abstract][Full Text] [Related]
14. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
[TBL] [Abstract][Full Text] [Related]
15. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
16. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Krege S; Giani G; Meyer R; Otto T; Rübben H
J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
[TBL] [Abstract][Full Text] [Related]
17. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
18. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
[TBL] [Abstract][Full Text] [Related]
19. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]